Review
Open access
Sep 2026
Effector-cell-engaging bispecific antibodies for cancer therapeutics: engineering precision immunity.
The bispecific antibody (bsAb) is a novel immune therapeutic platform that consists of a single molecule that simultaneously binds two distinct antigens, tumor-associated antigens and immune effector cells, to enhance the targeted killing of tumor cells. bsAbs can target T cells and natural killer (NK) cells or macroph...
A. Gholap, P. Khuspe, Darshana Morankar et al.
· Drug Discovery Today · 0 citations